

AAS

At page 36, line 1, please insert --ABSTRACT--;

N^e At page 36, line 3, please insert the following paragraph: --The tumor-associated antigen CAMEL and DNA encoding the antigen are provided. The tumor-associated antigen is encoded by an open reading frame of the LAGE-1 gene. The tumor associated antigen, immunogenic (poly)peptides derived therefrom and DNAs encoding them, are useful for cancer immunotherapy.--.

In the Claims:

Please cancel claims 1-14 without prejudice or disclaimer.

Please add the following claims:

-
- AAG
15. (New) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2.
 16. (New) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 26.
 17. (New) The isolated polypeptide of claim 16 comprising SEQ ID NO: 11.
 18. (New) The isolated polypeptide of claim 16 comprising SEQ ID NO: 12.
 19. (New) The isolated polypeptide of claim 16 comprising SEQ ID NO: 24.
 20. (New) The isolated polypeptide of claim 16 comprising SEQ ID NO: 25.
 21. (New) The isolated polypeptide of claim 16 comprising SEQ ID NO: 26.

22. (New) A composition comprising the polypeptide of claim 15 and a pharmaceutically acceptable carrier.
23. (New) A composition comprising the polypeptide of claim 16 and a pharmaceutically acceptable carrier.
24. (New) An isolated nucleic acid molecule encoding the polypeptide of claim 15.
25. (New) The nucleic acid molecule of claim 24 comprising the coding region of SEQ ID NO:1.
26. (New) The isolated nucleic acid molecule of claim 25 comprising SEQ ID NO. 1.
27. (New) An isolated nucleic acid molecule encoding the polypeptide of claim 16.
28. (New) A composition comprising the nucleic acid molecule of claim 24 and a pharmaceutically acceptable carrier.
29. (New) A composition comprising the nucleic acid molecule of claim 27 and a pharmaceutically acceptable carrier.
30. (New) A vector comprising the nucleic acid molecule of claim 24.
31. (New) A vector comprising the nucleic acid molecule of claim 27.
32. (New) A host cell comprising the vector of claim 30.

33. (New) A host cell comprising the vector of claim 31.
34. (New) A method for inducing a cytotoxic T lymphocyte response *in vivo* comprising administering to an individual in need thereof an effective amount of the polypeptide of claim 15 or an effective amount of a polynucleotide encoding said polypeptide.
35. (New) A method for inducing a cytotoxic T lymphocyte response *in vivo* comprising administering to an individual in need thereof an effective amount of the polypeptide of claim 16 or an effective amount of a polynucleotide encoding said polypeptide.
36. (New) An *ex vivo* method for treating an individual comprising
 - (a) incubating cytotoxic T lymphocyte (CTL) precursor cells obtained from the individual with antigen presenting cells and the polypeptide of claim 15;
 - (b) allowing said precursor cells to mature and expand to effector CTLs; and
 - (c) readministering said effector CTLs to the individual.
37. (New) An *ex vivo* method for treating an individual comprising
 - (a) incubating cytotoxic T lymphocyte (CTL) precursor cells obtained from the individual with antigen presenting cells and the polypeptide of claim 16;
 - (b) allowing said precursor cells to mature and expand to effector CTLs; and
 - (c) readministering said effector CTLs to the individual.

38. (New) An *ex vivo* method for treating an individual comprising administering to the individual cells transfected with the nucleic acid molecule of claim 24.
39. (New) An *ex vivo* method for treating an individual comprising administering to the individual cells transfected with the nucleic acid molecule of claim 27.
-

cancel